Insider Selling: DexCom, Inc. (DXCM) CEO Sells 6,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $115.73, for a total value of $694,380.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin R. Sayer also recently made the following trade(s):

  • On Monday, April 15th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $118.91, for a total value of $713,460.00.
  • On Tuesday, March 12th, Kevin R. Sayer sold 32,566 shares of DexCom stock. The stock was sold at an average price of $142.83, for a total value of $4,651,401.78.

Shares of DexCom stock traded up $4.00 on Tuesday, hitting $120.25. The stock had a trading volume of 572,327 shares, compared to its average volume of 1,347,384. DexCom, Inc. has a twelve month low of $85.43 and a twelve month high of $156.16. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of 400.83 and a beta of 0.73.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.12. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The company had revenue of $280.50 million for the quarter, compared to the consensus estimate of $246.10 million. During the same quarter in the prior year, the business earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 52.1% on a year-over-year basis. As a group, equities research analysts predict that DexCom, Inc. will post 0.76 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research report on Tuesday, April 30th. Piper Jaffray Companies boosted their price target on DexCom to $173.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. BidaskClub downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. Raymond James lowered their price target on DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, BMO Capital Markets boosted their price target on DexCom from $167.00 to $172.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $152.25.

Institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can grew its position in DexCom by 141.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 24,305 shares of the medical device company’s stock worth $2,780,000 after buying an additional 14,225 shares in the last quarter. Virginia Retirement Systems ET AL grew its position in DexCom by 230.6% during the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock worth $1,929,000 after buying an additional 11,300 shares in the last quarter. Two Sigma Advisers LP grew its position in DexCom by 1,493.1% during the fourth quarter. Two Sigma Advisers LP now owns 694,814 shares of the medical device company’s stock worth $83,239,000 after buying an additional 651,200 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its position in DexCom by 33.2% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 181,252 shares of the medical device company’s stock worth $21,714,000 after buying an additional 45,149 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in DexCom during the fourth quarter worth approximately $442,000. 97.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Insider Selling: DexCom, Inc. (DXCM) CEO Sells 6,000 Shares of Stock” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.wkrb13.com/2019/05/15/insider-selling-dexcom-inc-dxcm-ceo-sells-6000-shares-of-stock.html.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.